| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2002; 41: 1303-1307
© 2002 British Society for Rheumatology
Original Papers |
Effectiveness of TNF-
blockade with infliximab in refractory Wegener's granulomatosis
Department of Rheumatology, University of Lübeck and Rheumaklinik Bad Bramstedt, Lübeck,
1 Department of Ophthalmology and
2 Department of Diagnostic Radiology, Christian Albrechts University of Kiel, Kiel, Germany
Objective. To study the effect of the chimeric monoclonal anti-tumour necrosis factor 
(TNF-) antibody infliximab in the induction of remission in six patients refractory to standard treatment with cyclophosphamide and corticosteroids. In four patients, other measures for treating refractory Wegener's granulomatosis (WG) that have been advocated previously, i.e. intensified cyclophosphamide therapy and additional intravenous immunoglobulin, were ineffective.
Methods. Patients received infliximab (3 mg/kg in two patients and 5 mg/kg in four patients) with a 2-week interval after the first administration and 4-week intervals between infusions until remission, in addition to cyclophosphamide and corticosteroids. Vasculitis activity was assessed with the Birmingham Vasculitis Activity Score (BVAS). A standardized interdisciplinary approach was used for the follow-up of specific organ involvement.
Results. Remission was induced in five patients and corticosteroid doses could be tapered. Acute-phase responses (e.g. C-reactive protein) normalized. Titres of c-ANCA (cytoplasmic pattern antineutrophil cytoplasmic antibodies) were no longer detectable. The BVAS was reduced to zero. The higher dose of infliximab (5 mg/kg) seemed more effective in inducing remission. One patient was withdrawn because of suspected systemic infection. Five patients remained in remission for 6–24 months of follow-up.
Conclusion. The data suggest that infliximab may provide an effective and more specific therapeutic option in the treatment of active WG refractory to standard treatment.
KEY WORDS: Wegener's granulomatosis, Treatment, Infliximab.
Correspondence to: P. Lamprecht, Department of Rheumatology, University of Lübeck, and Rheumaklinik Bad Bramstedt, Ratzeburger Allee 160, 23538 Lübeck, Germany.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. R Sangle, G. R V Hughes, and D. P D'Cruz Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects Ann Rheum Dis, April 1, 2007; 66(4): 564 - 565. [Full Text] [PDF]
|
|
|
|
 |
|
 S. L Johnston Biologic therapies: what and when? J. Clin. Pathol., January 1, 2007; 60(1): 8 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. R. Wilkinson, E. Erendzhinova, A. Zeft, and D. A. Cabral Infliximab as rescue therapy in three cases of paediatric Wegener's granulomatosis Rheumatology, August 1, 2006; 45(8): 1047 - 1048. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Feldmann and C. D. Pusey Is There a Role for TNF-{alpha} in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis? Lessons from Other Chronic Inflammatory Diseases J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1243 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Foster, E Rosenthal, S Marques, P Vounotrypidis, S Sangle, and D D'Cruz Primary systemic vasculitis: treatment of difficult cases Lupus, March 1, 2006; 15(3): 143 - 147. [Abstract] [PDF]
|
|
|
|
 |
|
 K. K. Brown Pulmonary vasculitis. Proceedings of the ATS, January 1, 2006; 3(1): 48 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S K Frankel, G P Cosgrove, and K K Brown Small vessel vasculitis of the lung Chronic Respiratory Disease, April 1, 2005; 2(2): 75 - 84. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Pfister, M. Ollert, L. F. Frohlich, L. Quintanilla-Martinez, T. V. Colby, U. Specks, and D. E. Jenne Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo Blood, September 1, 2004; 104(5): 1411 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Booth, L. Harper, T. Hammad, P. Bacon, M. Griffith, J. Levy, C. Savage, C. Pusey, and D. Jayne Prospective Study of TNF{alpha} Blockade with Infliximab in Anti-Neutrophil Cytoplasmic Antibody-Associated Systemic Vasculitis J. Am. Soc. Nephrol., March 1, 2004; 15(3): 717 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rozin Infliximab efficiency in refractory Wegener's granulomatosis Rheumatology, September 1, 2003; 42(9): 1124 - 1125. [Full Text] [PDF]
|
|
|
|
|
|
P. Lamprecht, J. Voswinkel, A. Gause, and W. L. Gross Reply Rheumatology, September 1, 2003; 42(9): 1125 - 1126. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Hellmich, E. Csernok, and W. L. Gross 20 years with ANCA (antineutrophil cytoplasmic autoantibodies): from seromarker to a major pathogenic player in vasculitis J. Leukoc. Biol., July 1, 2003; 74(1): 1 - 2. [Full Text] [PDF]
|
|